Unicycive Therapeutics (UNCY)
(Real Time Quote from BATS)
$4.16 USD
-0.05 (-1.19%)
Updated Aug 6, 2025 03:54 PM ET
After-Market: $4.14 -0.02 (-0.48%) 4:18 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
UNCY 4.16 -0.05(-1.19%)
Will UNCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for UNCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UNCY
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
UNCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for UNCY
Unicycive Therapeutics (UNCY) Publishes Promising Trial Data on CKD Treatment | UNCY Stock News
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data ...
Unicycive Therapeutics announces publication of OLC trial data
Unicycive Therapeutics: Manageable CMC Speed Bump - Pill Burden Edge Intact, Buying
Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying